WATCHMAN FLX Pro device with white background.


Left Atrial Appendage Closure Device

featuring HEMOCOATTM Technology

Clinical data

Recent studies

Pre-clinical data

The fluoropolymer-coated WATCHMAN FLX Pro device showed significantly less thrombus and reduced inflammation in a challenging canine model. Mechanistic studies demonstrated that the WATCHMAN FLX Pro device binds more albumin, leading to reduced platelet activation, less inflammation, and greater endothelial coverage (EC).1

WATCHMAN FLX device with decorative teal overlay
  1. Saliba et al. Enhanced Thromboresistance and Endothelialization of a Novel Fluoropolymer-Coated Left Atrial Appendage Closure Device, JACC: Clinical Electrophysiology, 2023.